RTI Biologics

News

Athersys licenses stem cell technology in deal worth up to $40M

RTI Biologics Inc. plans to develop and commercialize implants based on Athersys' Multipotent Adult Progenitor Cell (MAPC) technology.

By Brandon Glenn

A Personalized Approach to Medication Nonadherence

At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.

Health Services

Maximize Revenue and Patient Care with Strategic Weight Loss Management

We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.

By Build My Health and MedCity News